How many MSM in Europe could benefit from PrEP – a 9 billion Euro question?

Beyrer C Baral SD van Griensven F . Global epidemiology of HIV infection in men who have sex with men. Lancet 2012; 380: 367–377.

Weller S and Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2001: CD003255.

Grant RM Lama JR Anderson PL . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587–2599.

Molina JM, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. In: Conference on retroviruses and opportunistic infections, Seattle, 23–26 February 2015.

McCormack S and Dunn D; on behalf of the PROUD study group. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. In: Conference on retroviruses and opportunistic infections, Seattle, 23–26 February 2015.

World Health Organization. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects, Geneva: World Health Organization, July 2012.

Centres for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014 clinical practice guideline, Atlanta: Centres for Disease Control and Prevention, 2014.

Weatherburn P Schmidt AJ Hickson F . The European Men-who-have-sex-with-men internet survey (EMIS): design and methods. Sex Res Soc Policy 2013; 10: 243–257.

Marcus U Hickson F Weatherburn P . Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses among MSM in 2009. BMC Publ Health 2013; 13: 919–919.

Marcus U Hickson F Weatherburn P . Prevalence of HIV among MSM in Europe: comparison of self-reported diagnoses from a large scale internet survey and existing national estimates. BMC Publ Health 2012; 12: 978–978.

Vernazza P Hirschel B Bernasconi E . Transmission under highly active antiretroviral therapy. Lancet 2008; 372: 1806–1807. author reply 7.

Gomez GB Borquez A Case KK . The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med 2013; 10: e1001401–e1001401.

Paltiel AD Freedberg KA Scott CA . HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48: 806–815.

Koppenhaver RT Sorensen SW Farnham PG . The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 2011; 58: e51–e52.

Desai K Sansom SL Ackers ML . Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22: 1829–1839.

Médecins Sans Frontières. Untangling the web of antiretroviral price reductions, Geneva, Switzerland: MSF, 2013.

Hill A Hill T Jose S . Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018. J Int AIDS Soc 2014; 17(4 Suppl 3): 19497–19497.

De Man J Colebunders R Florence E . What is the place of pre-exposure prophylaxis in hiv prevention? AIDS Rev 2013; 15: 102–111.

Stolte IG Dukers NH Geskus RB . Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18: 303–309.